To see when there is a difference in enough time from cancer medical diagnosis to initiation of treatment for African American men compared with Caucasian guys with prostate cancer, Ronald Chen, MD, MPH, of the University of NEW YORK at Chapel Hill, and his colleagues analyzed data from the Surveillance, Epidemiology and FINAL RESULTS -Medicare registry, which links cancer analysis data to a grasp file of Medicare records. Their analysis included 2,506 African American and 21,454 Caucasian sufferers identified as having early prostate cancers from 2004 to 2007 and treated within 12 months of analysis. Related StoriesCrucial change in single DNA foundation predisposes children to intense form of cancerFDA grants accelerated authorization for Tagrisso to treat individuals with advanced NSCLCNew results reveal association between colorectal cancer and melanoma medications On average, the time from prostate cancer analysis to initiation of treatment was a week longer overall for African American individuals weighed against Caucasian patients.The median time until the initiation of cytotoxic chemotherapy was 28.0 months in the enzalutamide group, in comparison with 10.8 months in the placebo group . Treatment with enzalutamide also led to a decrease in the risk of an initial skeletal-related event, which occurred in 278 patients in the enzalutamide group and 309 patients in the placebo group in a median of approximately 31 months in each one of the two groups . Among patients with measurable soft-cells disease at baseline, 59 percent of the patients in the enzalutamide group, as compared with 5 percent in the placebo group, had an objective response : complete and partial responses were observed in 20 percent and 39 percent of the patients, respectively, in the enzalutamide group, in comparison with 1 percent and 4 percent, respectively, in the placebo group.